作者: Xiaohong Jiang , Dongxia Hou , Zhe Wei , Shasha Zheng , Yujing Zhang
DOI: 10.1186/S41544-019-0014-0
关键词:
摘要: Pancreatic cancer (PaC) is one of the most aggressive malignancies. The dismal survival rate PaC patients mainly due to late diagnosis and their resistance conventional chemotherapies. Emerging evidence suggests that miRNA can serve as a potential new diagnostic therapeutic weapon fight against PaC. Circulating miRNAs represent promising noninvasive tools for owing high stability in blood. Combinations circulating with other serum indicators such carbohydrate antigen 19–9 (CA19–9) were demonstrated be valuable biomarkers early diagnosis. As regulate epithelial-mesenchymal transition (EMT) progression stem cells (CSCs), two critical factors drug resistance, selectively manipulating may improve sensitivity certain chemotherapeutic agents, gemcitabine. Therefore, investigations provide novel approaches both tumor treatment.